BioCentury | Dec 4, 2020
Finance

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

...was president and CEO of cancer company Quanticel Pharmaceuticals Inc....
BioCentury | Dec 20, 2019
Financial News

Combining kinase biology with precision oncology, Kinnate raises $75M series B

...patient selection technology. Co-founder and CEO Stephen Kaldor was president and CEO of cancer company Quanticel Pharmaceuticals Inc....
BioCentury | Nov 30, 2018
Company News

Genentech acquiring Versant-backed NASH play Jecure

...Stafford and CSO James Veal, both of whom were senior executives at Versant portfolio company Quanticel Pharmaceuticals Inc....
BioCentury | Nov 27, 2018
Company News

Genentech acquiring Versant-backed NASH play Jecure

...Stafford and CSO James Veal, both of whom were senior executives at Versant portfolio company Quanticel Pharmaceuticals Inc....
BioCentury | Aug 17, 2017
Finance

Built to purpose

...LLC Eli Lilly and Co. (NYSE:LLY) Atlas Venture Neurology Single asset $18 ND 2011 2013 Quanticel Pharmaceuticals Inc....
...director at Versant. Versant has signed eight build-to-buys since its 2011 agreement with Celgene on Quanticel Pharmaceuticals Inc....
BioCentury | Feb 17, 2017
Finance

Fast start in NASH

...Veal, who were both part of the senior management team at Versant’s first build-to-buy company, Quanticel Pharmaceuticals Inc....
BioCentury | Feb 15, 2017
Financial News

NASH play Jecure raises $20M in debut

...Jeffrey Stafford and CSO James Veal were on the management team at Versant-backed cancer company Quanticel Pharmaceuticals Inc....
BioCentury | Dec 31, 2016
Finance

Versant’s capstone

...over which we transitioned the model and proved it with our returns.” Brad Bolzon, Versant Quanticel Pharmaceuticals Inc....
BioCentury | May 4, 2015
Finance

Build to bye-bye

...wisely." The firm kicked off last week with news that Celgene is buying portfolio company Quanticel Pharmaceuticals Inc....
BioCentury | May 4, 2015
Company News

Quanticel Pharmaceuticals, Celgene deal

...2011 deal, which also gave Celgene an undisclosed equity stake (see BioCentury, Nov. 7, 2011). Quanticel Pharmaceuticals Inc....
Items per page:
1 - 10 of 21
BioCentury | Dec 4, 2020
Finance

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

...was president and CEO of cancer company Quanticel Pharmaceuticals Inc....
BioCentury | Dec 20, 2019
Financial News

Combining kinase biology with precision oncology, Kinnate raises $75M series B

...patient selection technology. Co-founder and CEO Stephen Kaldor was president and CEO of cancer company Quanticel Pharmaceuticals Inc....
BioCentury | Nov 30, 2018
Company News

Genentech acquiring Versant-backed NASH play Jecure

...Stafford and CSO James Veal, both of whom were senior executives at Versant portfolio company Quanticel Pharmaceuticals Inc....
BioCentury | Nov 27, 2018
Company News

Genentech acquiring Versant-backed NASH play Jecure

...Stafford and CSO James Veal, both of whom were senior executives at Versant portfolio company Quanticel Pharmaceuticals Inc....
BioCentury | Aug 17, 2017
Finance

Built to purpose

...LLC Eli Lilly and Co. (NYSE:LLY) Atlas Venture Neurology Single asset $18 ND 2011 2013 Quanticel Pharmaceuticals Inc....
...director at Versant. Versant has signed eight build-to-buys since its 2011 agreement with Celgene on Quanticel Pharmaceuticals Inc....
BioCentury | Feb 17, 2017
Finance

Fast start in NASH

...Veal, who were both part of the senior management team at Versant’s first build-to-buy company, Quanticel Pharmaceuticals Inc....
BioCentury | Feb 15, 2017
Financial News

NASH play Jecure raises $20M in debut

...Jeffrey Stafford and CSO James Veal were on the management team at Versant-backed cancer company Quanticel Pharmaceuticals Inc....
BioCentury | Dec 31, 2016
Finance

Versant’s capstone

...over which we transitioned the model and proved it with our returns.” Brad Bolzon, Versant Quanticel Pharmaceuticals Inc....
BioCentury | May 4, 2015
Finance

Build to bye-bye

...wisely." The firm kicked off last week with news that Celgene is buying portfolio company Quanticel Pharmaceuticals Inc....
BioCentury | May 4, 2015
Company News

Quanticel Pharmaceuticals, Celgene deal

...2011 deal, which also gave Celgene an undisclosed equity stake (see BioCentury, Nov. 7, 2011). Quanticel Pharmaceuticals Inc....
Items per page:
1 - 10 of 21